Xilio Therapeutics, Inc. XLO
Xilio Therapeutics, Inc. (Nasdaq: XLO) is an oncology drug developer. Its lead program, efarindodekin alfa (masked IL-12), is in Phase 2 for advanced solid tumors. Its next catalyst on record is XTX501: initiate dosing Phase 1/2 (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: XTX501 — initiate dosing Phase 1/2 (H2 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| efarindodekin alfa | advanced solid tumors (Phase 2, Gilead license) | protein/peptide | Phase 2 |
| vilastobart (XTX101) | solid tumors with atezolizumab | antibody | Phase 1 |
| XTX501 | NSCLC/solid tumors (PD-1/masked IL-2) | antibody | Phase 1 |
| masked TCEs | solid tumors | biologic-other | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.